ArticlePharmacoEconomics2015
The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.
Article in PharmacoEconomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Mapping to estimate health state utility: a systematic review of development and limitations.Health and quality of life outcomes · 2025Pooled it
- A systematic review of condition-specific preference-based measures used in young people and their valuation methods.Journal of patient-reported outcomes · 2024Pooled it
- Quality appraisal for systematic literature reviews of health state utility values: a descriptive analysis.BMC medical research methodology · 2022Pooled it
- A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D.PharmacoEconomics · 2018Pooled it
- Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement.Health and quality of life outcomes · 2018Pooled it
- Estimating pain visual analogue scale from health assessment questionnaire for rheumatoid arthritis with beta mixture models.Rheumatology international · 2025Trial
- Estimating health related quality of life effects in vitiligo. Mapping EQ-5D-5 L utilities from vitiligo specific scales: VNS, VitiQoL and re-pigmentation measures using data from the HI-Light trial.Health and quality of life outcomes · 2023Trial
- Mapping the Edmonton Symptom Assessment System-Revised: Renal to the EQ-5D-5L in patients with chronic kidney disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Trial
- Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Trial
- Mapping EORTC-QLQ-C30 scores to EQ-5D-5L utility values for gynecological cancer survivors in follow-up care.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Predicting EuroQol (EQ-5D-5 L) health state utilities from functional outcomes of sleep questionnaire (FOSQ-10) scores.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Mapping the NEI-VFQ-25 scores to the EQ-5D-Y-3L and CHU-9D utility values among adolescents with myopia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Relationship between Dermatology Life Quality Index Scores and EQ-5D-5L Utility Values in Adults with Atopic Dermatitis: Development of a Swedish Mapping Model.Acta dermato-venereologica · 2026Article
- Article
- Mapping of the EORTC QLQ-LC43 to EQ-5D-5 L index in patients with lung cancer: comparison of traditional regression models with machine learning technique.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Estimating QALYs in adults with cerebral palsy: mapping the San Martin scale to the EQ-5D-5L for economic evaluation.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria.PharmacoEconomics · 2026Article
- Mapping of QLQ-C30 and QLQ-PR25 Scores to EQ-5D-5L Utility Values for Patients with Prostate Cancer Receiving Novel Androgen Receptor Signaling Inhibitors.European urology open science · 2026Article
- Development of a PRISMA extension for systematic reviews of health economic evaluations (PRISMA-EconEval): a project protocol.Systematic reviews · 2025Article
- Mapping the EORTC QLQ-C30 and QLQ-LC13 to the SF-6D utility index in patients with lung cancer using machine learning and traditional regression methods.Health and quality of life outcomes · 2025Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe process of "mapping" is increasingly being used to predict health utilities, for application within health economic evaluations, using data on other indicators or measures of health. Guidance for the reporting of mapping studies is currently lacking.
objectiveThe overall objective of this research was to develop a checklist of essential items, which authors should consider when reporting mapping studies. The MAPS (MApping onto Preference-based measures reporting Standards) statement is a checklist, which aims to promote complete and transparent reporting by researchers. This paper provides a detailed explanation and elaboration of the items contained within the MAPS statement.
methodsIn the absence of previously published reporting checklists or reporting guidance documents, a de novo list of reporting items and accompanying explanations was created. A two-round, modified Delphi survey, with representatives from academia, consultancy, health technology assessment agencies and the biomedical journal editorial community, was used to identify a list of essential reporting items from this larger list.
resultsFrom the initial de novo list of 29 candidate items, a set of 23 essential reporting items was developed. The items are presented numerically and categorised within six sections, namely, (i) title and abstract, (ii) introduction, (iii) methods, (iv) results, (v) discussion and (vi) other. For each item, we summarise the recommendation, illustrate it using an exemplar of good reporting practice identified from the published literature, and provide a detailed explanation to accompany the recommendation.
conclusionsIt is anticipated that the MAPS statement will promote clarity, transparency and completeness of reporting of mapping studies. It is targeted at researchers developing mapping algorithms, peer reviewers and editors involved in the manuscript review process for mapping studies, and the funders of the research. The MAPS working group plans to assess the need for an update of the reporting checklist in 5 years' time.
Indexed as
Identifiers
26232200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.